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In the developing CNS α- and β-dystroglycan are highly concentrated in the endfeet of radial neuroepithelial cells at the contact site to the
basal lamina. We show that injection of anti-dystroglycan Fab fragments, knockdown of dystroglycan using RNAi, and overexpression of a
dominant-negative dystroglycan protein by microelectroporation in neuroepithelial cells of the chick retina and optic tectum in vivo leads to the
loss of their radial morphology, to hyperproliferation, to an increased number of postmitotic neurons, and to an altered distribution of several
basally concentrated proteins. Moreover, these treatments also altered the oriented growth of axons from retinal ganglion cells and from tectal
projection neurons. In contrast, expression of non-cleavable dystroglycan protein in neuroepithelial cells reduced their proliferation and their
differentiation to postmitotic neurons. These results demonstrate that dystroglycan plays a key role in maintaining neuroepithelial cell morphology,
and that interfering with dystroglycan function influences proliferation and differentiation of neuroepithelial cells. These data also suggest that an
impaired dystroglycan function in neuroepithelial cells might be responsible for some of the severe brain abnormalities observed in certain forms
of congenital muscular dystrophy.
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The dystrophin-associated glycoprotein complex (DGC) is a
large and heteromeric protein complex which is widely
expressed in many tissues. The central protein of all DGCs is
dystroglycan, a membrane-associated receptor expressed in
many tissues, with a complex structure and biosynthesis (for
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the precursor protein by an unknown protease during or shortly
after translation generates two subunits, α-dystroglycan and β-
dystroglycan (Ibraghimov-Beskrovnaya et al., 1992). The β-
dystroglycan subunit is a 43 kDa transmembrane protein with a
single membrane spanning region. In contrast, α-dystroglycan
is a heavily glycosylated extracellular protein with a molecular
mass varying between 120 and 180 kDa, depending on the
degree of glycosylation. In skeletal muscle, β-dystroglycan
binds intracellularly with its C-terminus to the β-spectrin/α-
actinin-like peripheral membrane proteins dystrophin or
utrophin (Huang et al., 2000). Dystrophin and utrophin interact
via their N-termini with the subsarcolemmal actin filaments
(Rybakova et al., 1996). On the extracellular side, β-
dystroglycan interacts non-covalently with α-dystroglycan
(Sciandra et al., 2001) and α-dystroglycan has the potential to
bind to several extracellular proteins, including laminin-1 and
-2, agrin, biglycan, perlecan, and neurexins (Sugiyama et al.,
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interactions enable the DGC to form a continuous molecular
link between the subsarcolemmal actin cytoskeleton and the
extracellular matrix. In skeletal muscle this link provides
mechanical stability to the muscle fibers particularly during
contraction and relaxation (Ervasti and Campbell, 1993).
Another function of the DGC is to provide a scaffold to
which proteins can bind and, thus, become localized to the
muscle fiber subsarcolemmal compartment (see for example
Rando, 2001; Spence et al., 2004; Judge et al., 2006).
Disruption of the DGC in skeletal muscle therefore has many
more consequences than just the loss of basal lamina attach-
ment. Accordingly, mutations which interfere with the function
of the DGC cause various forms of muscular dystrophy, often
fatal diseases characterized primarily by a progressive weaken-
ing and loss of skeletal muscle tissue (Dalkilic and Kunkel,
2003).
Dystroglycan and other DGC proteins are also expressed in
non-muscle tissues, including the central nervous system (Blake
and Kröger, 2000; Cohn, 2005). Accordingly, muscular
dystrophies are frequently associated with a wide spectrum of
CNS defects (Anderson et al., 2002). The CNS deficits are
particularly severe in recently identified dystroglycanopathies,
which include three forms of congenital muscular dystrophies:
Walker–Warburg Syndrome, Muscle–Eye–Brain disease and
Fukuyama-Congenital Muscular Dystrophy (Muntoni et al.,
2004). These diseases are caused by mutations in glycosyl-
transferases that have α-dystroglycan as one of their main
substrates in the CNS (Michele et al., 2002; Moore et al., 2002;
Martin-Rendon and Blake, 2003). The CNS abnormalities in
patients or animals with mutations in any of the glycosyl-
transferases are severe and include mental retardation, poly-
microgyria, defects in neuronal migration, disorganization of
CNS lamination, various degrees of cortical dysplasia, and
extrusion of neuronal and glial tissue into the subarachinoidal
space through breaches of the pia basal lamina (the glia limitans
separating the brain parenchyma from the subarachinoid space;
Yoshida et al., 2001; Beltran-Valero et al., 2002; Michele et al.,
2002; Muntoni et al., 2004). Ocular abnormalities including a
loss of the normal histoarchitecture and layering, hyperproli-
feration, altered neuronal migration and differentiation and
retinal detachment are also frequently observed (Longman et
al., 2003; Takeda et al., 2003; Beltran-Valero de Bernabe et al.,
2004; Lee et al., 2005). Thus, a stable association of α-
dystroglycan with the extracellular matrix via its carbohydrate
side chains appears to be necessary for normal CNS develop-
ment. However, the specific functions of dystroglycan,
particularly in the early developing CNS, and the mechanism,
that lead to the severe brain abnormalities in congenital
muscular dystrophies are unknown.
Neuroepithelial cells are the principal cells of the neural plate
and neural tube and represent the precursor cells for neurons and
glial cells in the developing CNS (for review see Kriegstein and
Götz, 2003; Götz and Huttner, 2005). Neuroepithelial cells have
a palisade-like morphology with their processes spanning the
entire width between the pial surface and the ventricle, and a
complex cell cycle which includes the translocation of thenucleus along the apical–basal axis by an interkinetic nuclear
migration, giving rise to the pseudostratified structure of the
neuroepithelium (Götz and Huttner, 2005). Neuroepithelial cells
are firmly attached to the pia basal lamina by an endfoot, and
previous studies have shown that dystroglycan and other
proteins of the DGC are highly concentrated in these endfeet
at the contact site to the basal lamina (Blank et al., 1997, 2002;
Zaccaria et al., 2001). In this study we analyzed the function of
the DGC in neuroepithelial cell endfeet in vivo using anti-
dystroglycan antibodies, knockdown of dystroglycan synthesis
with RNAi and overexpression of mutated dystroglycan cDNAs
by in ovo electroporation. Our results show that dystroglycan is
crucial for anchoring neuroepithelial cell endfeet to the basal
lamina and for neuroepithelial cell morphology, proliferation
and differentiation. Furthermore, our results also suggest that
some of the brain abnormalities observed in some congenital
muscular dystrophies might be caused by interfering with
dystroglycan function at the endfoot–basal lamina interface.Materials and methods
Animals
Fertile White Leghorn (Gallus gallus domesticus) chicken eggs were
purchased from a local hatchery and incubated at 38 °C in a humid atmosphere.
The age of the embryos was expressed as embryonic day (E) or according to the
stages defined by Hamburger and Hamilton (HH; Hamburger and Hamilton,
1951). All experiments were conducted in accordance with the guidelines for the
welfare of experimental animals issued by the Federal Government of Germany
and the University of Mainz.
Cloning of chick dystroglycan
A cDNA coding for full-length chick dystroglycan was isolated from an
embryonic chick muscle library by PCR using degenerate primers in
combination with 5′RACE (System 2.0; Invitrogen, Karlsruhe, Germany).
The 3′ end of chick dystroglycan was isolated from a COSMID (obtained from
the German Research Center for Genome Research, RZPD, Heidelberg,
Germany). The final cDNA had a length of 2933 base pairs (125 bp 5′-UTR,
117 bp 3′-UTR) and contained an open reading frame coding for 896 amino
acids. The sequence was between 78% and 93% homologous to the
corresponding sequences from rabbit, human, bovine, and mouse. In particular
the predicted cleavage site between α- and β-dystroglycan at serine 655 was
conserved (Esapa et al., 2003). The full-length sequence of chick dystroglycan
has been deposited in the EMBL database (accession number: AM690436).
Antibodies and immunocytochemistry
The following primary antibodies were used: A monoclonal mouse anti-β-
dystroglycan antibody (43DAG/8D5; Novocastra, Newcastle-upon-Tyne, UK),
which recognizes 15 of the last 16 amino acids at the C-terminus of dystroglycan
and cross-reacts with human, mouse, rat, bovine, rabbit and chick tissue; a
monoclonal antibody against vimentin (VIM 3B4; Boehringer Ingelheim,
Ingelheim, Germany); a monoclonal antibody against BrdU (clone Bu20a;
DAKO Cytomation GmbH, Göttingen, Germany); a monoclonal antibody
against acetylcholine esterase (AChE; mAb 3D10; Randall et al., 1987); a rabbit
polyclonal antiserum against EGFP (Molecular Probes, Eugene, Oregon); a
sheep polyclonal antiserum against the core protein of α-dystroglycan
(Herrmann et al., 2000); a monoclonal antibody against the integrin β1-subunit
(clone JG22; Sigma); a mouse monoclonal anti-utrophin antibody (mAb20C5;
Bewick et al., 1992); a rabbit anti-α-dystrobrevin-1 antiserum (Blake et al.,
1998); and a mouse anti-Ng-CAM monoclonal antibody (G4; Rathjen et al.,
1987).
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sectioned and stained as described previously (Kröger, 1997). The primary
antibodies were visualized using the appropriate secondary antibody conjugated
to Alexa488 or Alexa594 fluorochromes, respectively, (Molecular Probes,
Eugene, Oregon), as described (Blank et al., 1997). The nuclei were stained
using bisbenzimide (Hoechst 33342 nuclear stain; Sigma) at a concentration of
10 μg/ml. Specimens were viewed using in a Leitz DMRA fluorescence
microscope (63× oil immersion lens) equipped with a digital camera (DX 200;
Leica, Solms, Germany) and an appropriate filter system for complete separation
of both fluorochromes. Whole images were processed and contrast as well as
brightness was adjusted using Adobe Photoshop (version 7.0, Adobe, Mountain
View, CA, USA). Control sections stained with the secondary antibodies alone
did not show any in specific immunoreactivity. Preabsorbed antisera were used
to avoid cross reactivity between the secondary antibodies.
Polyclonal anti-dystroglycan antisera were generated in rabbits against a
bacterially-expressed fusion protein of amino acid 564–749 or amino acid 555–
749 inserted into the pET28a vector (Novagen, Madison, USA) and expressed in
BL21 bacteria (Stratagene, La Jolla, USA). The vector contained a 6xHis
epitope tag at the N- and C-terminus allowing affinity purification using the
BugBuster- and the His-Bind Purification System (Novagen). The fusion protein
appeared homogeneous as a single band after Coomassie blue staining. Two
rabbits were immunized with each of the two purified fusion proteins. Sera were
obtained after 175 days of immunization. The antisera were affinity-purified first
using Protein A and then using the fusion protein coupled to sepharose-CL4B.
Finally, Fab fragments were prepared from the affinity-purified IgG fraction
using the ImmunoPure Fab-purification System (Pierce, Bonn, Germany). Fab
fragments were dialyzed against PBS and concentrated using Centricon tubes
(Amicon, Witten, Germany). All four antisera specifically detected α- as well as
β-dystroglycan in Western blots of transfected cells and of muscle and brain
tissue. Moreover, the antisera also stained the sarcolemmal plasma membrane in
embryonic and adult muscle tissue, the inner limiting membrane and the outer
plexiform layer of the retina, and the glia limitans and blood vessels in the entire
CNS. Thus, the staining pattern obtained with these antisera was indistinguish-
able from the pattern described previously for α- and β-dystroglycan in muscle,
retina and CNS tissue (Herrmann et al., 2000; Blank et al., 1997, 2002; Zaccaria
et al., 2001), demonstrating that the antisera specifically detect dystroglycan.
The two fusion proteins used for immunization of the 4 rabbits contained the
interaction site between α- and β-dystroglycan (Sciandra et al., 2001; Bozzi et
al., 2001). The antisera were therefore tested if they inhibit the interaction
between α- and β-dystroglycan in vitro using a co-immunoprecipitation assay.
Fab fragments prepared from three out of the four antisera specifically inhibited
the co-immunoprecipitation of the fusion protein with recombinantly expressed
α-dystroglycan consistent with the idea that they inhibited the interaction
between α- and β-dystroglycan (Figure S1 in supplementary material). These
three independently prepared Fab fragments were subsequently used and gave
identical results in all experiments.
The anti-dystroglycan Fab fragments were injected into the embryonic chick
eye or tectum as described previously (Kröger et al., 1996). Between 0.2 and
1.9 μg (in a volume between 1 and 10 μl) of affinity-purified Fab fragments were
injected once every day for 3 consecutive days between E4 and E9. Twenty-four
hours after the final injection, embryos were sacrificed and the retina or tectum
was dissected and analyzed. BrdU labeling of cells was performed by applying
100 μl of BrdU (10 mg/ml) for 3 h as described (Belecky-Adams et al., 1996).
Mutant dystroglycan cDNAs
Twomutant chick dystroglycan cDNAs were used in this study in addition to
wild type dystroglycan (wt-dystroglycan) and the empty pMES vector. In one
cDNA the cleavage site between the α- and the β-dystroglycan subunit was
mutated by changing serine at position 655 to alanine (non-cleavable
dystroglycan). This construct has been extensively characterized previously
and shown to be transported to the plasma membrane and inserted in the
appropriate orientation in transfected HEK293 cells (Esapa et al., 2003).
Heterologous expression of this construct in HEK cells resulted in the synthesis
of a protein with a molecular weight of 160 kDa as determined with an antibody
against β-dystroglycan (Esapa et al., 2003). Likewise, expression of the
construct in chick embryos by in ovo electroporation induced the synthesis of a
β-dystroglycan-reactive protein of the same size, demonstrating the synthesis ofdystroglycan in neuroepithelial cells as well as the absence of proteolytic
processing of the mutated protein also in chick embryos in vivo (Figure S2 in
supplementary material).
A second dystroglycan construct was generated by deleting the intracellular
C-terminal most 15 amino acid of β-dystroglycan (truncated dystroglycan), and
thus, removing the interaction site between β-dystroglycan and dystrophin or
utrophin (Jung et al., 1995). This construct was generated using PCR and the
following primers: DG-Δ15C-sense 5′-TCTAGAATGACTGTTG-
GATGTGTCCCGCAGC-3′ and DG-Δ15C-antisense 5′-GGATCCCTAGATC-
TTATCGTCGTCATCCTTGTAATCCATCGGGCGGGAGC-3′. The PCR
reaction product was blunt-end cloned first into the pcDNA4/TO vector
(Invitrogen, Karlsruhe, Germany). All dystroglycan constructs were then cloned
into the bicistronic pMES vector (Swartz et al., 2001), that contains an internal
ribosome entry site regulating the simultaneous expression of the gene of
interest together with the enhanced green fluorescent protein (EGFP). This
allowed the convenient distinction of transfected from untransfected cells. All
constructs used in this study were routinely sequenced to eliminate the
possibility of mutations.
In ovo electroporation
We used in ovo electroporation to analyze the function of dystroglycan in
vivo during very early stages of CNS development. Microelectroporation of
retinal neuroepithelial cells was performed as described previously (Momose et
al., 1999). In short, 2 μg cDNA in approximately 0.5 μl PBS were injected into
the optic stalk at E2 (HH stage 11). The left side of the embryo was then
transfected by application of 5 square pulses of 15 V and 25 ms duration with
100 ms pulse interval using a BTX-830 pulse generator (BTX, San Diego, USA)
in combination with a tungsten cathode (40 μm sharp tip), inserted into the
ventricle through the neuropore, and a 5 mm gold electrode as anode placed
laterally along the left side of the embryo. The chicken eggs were then sealed
and further incubated for 1–5 days. Unless stated otherwise, embryos were
examined 4 days after electroporation at E6. Analysis of the embryos showed
that only the left side of the embryos was transfected and therefore the
contralateral right side was always used as an internal control. Approximately
70% of the embryos were successfully transfected and in 50% of the embryos
more than half of the retinal cells were transfected as determined by the presence
of EGFP fluorescence.
RNAi knock-down of dystroglycan
Dystroglycan synthesis was inhibited posttranscriptionally using either long
dsRNA or 21mer siRNA oligonucleotides followed by in ovo electroporation.
Both approaches gave similar results. Long dsRNAi were generated by selecting
three regions of the dystroglycan cDNA (two within the α-dystroglycan and one
within the β-dystroglycan subunit) each with a length between 700 and 800 bp
as targets and amplified using PCR and the following primers:
α-DG1-sense 5′-GCTCTAGAAGGACTTTGCTCCCAGTGC-3′;
α-DG1-antisense 5′-GGGGTACCTTCCACCACCTTCTTTGC-3′;
α-DG2-sense 5′-GCTCTAGAGAAGGCACTGGGACGGTC-3′;
α-DG2-antisense 5′-GGGGTACCGATGGTGCTGCTGTTCC-3′;
β-DG1-sense 5′-GTCCTAGAACCAACAACACCCTGC-3′ and
β-DG1-antisense 5′-GGGGTACCGGTCATGTTCTTCG-3′
The sequences covered different non-overlapping parts of the entire
dystroglycan cDNA. The amplification products were cloned into the pSP72
vector (Promega, Mannheim, Germany) and single-strand RNAs were generated
by in vitro transcription using the SP6 and T7 promoter according to the
manufacturer's instructions (Promega). dsRNA was obtained by mixing
equimolar amounts of the complementary single-strand RNAs and subsequent
heating followed by slow cooling.
Since long dsRNAi might have unspecific effects and since their inhibitory
effects are difficult to quantify due to the activation of the interferon-mediated
apoptosis pathways, we repeated the experiments using two synthetic double-
stranded small interfering RNA (siRNA) targeting dystroglycan (Qiagen,
Hilden, Germany). The following dsRNA were used: siRNA-dag1 targeting
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CACGUUCAUUAAGAA)dTdT and antisense 5′r(UUGUCGUAGAAA-
GUAUCCG)dAdG; siRNA-dag2 targeting the β-dystroglycan sequence
between nucleotide 2364 and 2384 sense 5′r(AGGCCACGUUCAUUAA-
GAA)dTdT and antisense 5′r(UUCUUAAUGAACGUGGCCU)dGdG. Two
siRNAs were used as negative controls. siRNA-tmagrn1 (targeting nuc-
leotide 5846 to 5866 of chick TM-agrin; Neumann et al., 2001) sense
r(GGCUUUAUUGGCUGUAUAA)dTdT antisense r(UUAUACAGCCA-
AUAAAGCC)dAdG and siRNA-tmagrn2 (targeting nucleotide 880 to 900 of
chick TM-agrin) sense r(GGACAAAUGCAAGGAUGAA)dTdT and antisense
r(UUCAUCCUUGCAUUUGUCC)dAdG. The full-length dystroglycan and
TM-agrin cDNAs were cloned into the psiCheck-2 vector (Promega, Madison,
WI) and the inhibitory effect of the siRNAs on dystroglycan translation was
determined using the Dual-Glo Luciferase Assay system (Kumar et al., 2003)
according to the manufacturer's instructions (Promega). Luminescence was
determined using a Veritas Microplate Luminometer (Turner Biosystems,
Sunnyvale, CA). Both siRNA reduced dystroglycan expression to 20.6±1.8%
(siRNA-dag1) and 23.1±5.6% (siRNA-dag2; mean±S.E.M. with N=4) of
control values. Both siRNA targeting TM-agrin did not have an influence on
dystroglycan expression, nor did the two siRNA targeting dystroglycan
influence TM-agrin expression.
Injection of the RNAi and in ovo electroporation was performed in principle
as described above. Approximately 0.5 μl containing 0.5 μg dsRNA were
injected into a stage HH 11 chick embryo optic stalk. A single square pulse of
15 V and 25 ms was applied to transfect neuroepithelial cells selectively on the
left side of the embryo. Cotransfection of the pMES vector, containing the EGFP
expression cassette under the control of the chicken β-actin promoter, allowed
the distinction of the transfected cells from untransfected cells.
All RNAi probes targeting dystroglycan reduced endogenous expression of
α- and β-dystroglycan in the chick retina in vivo as determined by
immunofluorescence using anti-dystroglycan antibodies and resulted in a
thickened neuroepithel. None of the control RNAi probes had a detectable effect
on dystroglycan expression and on the morphology of the neuroepithelium.Results
Inhibition of dystroglycan function causes thickening of the
neuroepithelium
As a first step to determine the function of dystroglycan in
neuroepithelial stem cells, affinity-purified Fab fragments
directed against the interaction site between α- and β-
dystroglycan were injected daily for 3 consecutive days into
the vitreous of live chick embryos. The injections were made
between E5 and E9 since at this developmental stage,
dystroglycan and the DGC are exclusively expressed by
neuroepithelial cells and concentrated in their endfeet at the
contact site to the inner limiting membrane (Blank et al., 2002),
the basal lamina that separates the neural retina from the vitreous
(Halfter et al., 1987). While injection of PBS, of the
corresponding preimmune sera, or of the antisera in combination
with an excess of the fusion protein used for immunization had
no influence on the structure and overall appearance of the retina
(Fig. 1A), injection of the affinity-purified anti-dystroglycan Fab
fragments resulted in severe changes of the retinal morphology.
The smooth surface of the retina–vitreous interface was lost and
this was accompanied by an increase in radial thickness of the
retina (Fig. 1B). The thickened retinal neuropil protruded into
the vitreous humor but the contact between the retina and the
pigment epithelium (dashed line in Figs. 1A, B) remained
unaltered. Although the number of thickenings observed in
injected retinae varied from experiment to experiment, wedetected at least one affected area inmore than 80% of the retinae
analyzed.
We next injected the affinity-purified Fab fragments into the
ventricle of the embryonic chick mesencephalon to determine if
a similar change in the neuroepithelium could also be induced in
other parts of the early developing CNS. While injection of PBS
or of Fab fragments from the preimmune sera had no effect on
the overall morphology of the tectal neuropil (Fig. 1C),
injection of the affinity-purified Fab fragments induced an
increase in the thickness of the mesencephalic neuroepithelium
(Fig. 1D), demonstrating similar effects of the Fab fragments in
the retina and in the tectum.
As an independent method to determine the role of
dystroglycan in neuroepithelial cells in vivo, we inhibited the
synthesis of dystroglycan using RNAi. Three non-overlapping
dsRNA fragments of 700 to 800 bp length, two corresponding
to the α-dystroglycan and one to the β-dystroglycan sequence,
as well as two different siRNA (one targeting α-dystroglycan
and one targeting β-dystroglycan) were injected into the optic
vesicle of stage 11 embryos and transfected into neuroepithelial
cells by in ovo microelectroporation (Momose et al., 1999).
Transfected areas were identified by the co-electroporation of a
plasmid coding for EGFP. The phenotypes obtained by RNAi
transfection using the 5 different dsRNAs were indistinguish-
able with respect to both quality and penetrance. Electropora-
tion of anti-α-dystroglycan (Fig. 1E) or anti-β-dystroglycan
(Fig. 1F) RNAi resulted in an increased thickness of the
neuroepithelial cell wall similar to that observed after injection
of anti-dystroglycan Fab fragments. Staining with antibodies
specifically against α- or β-dystroglycan (Figs. 1E, F, respect-
ively) showed the severe reduction of dystroglycan immunor-
eactivity co-distributing with areas of increased neuroepithelial
thickness. A similar phenotype was never observed after
injection and electroporation of control dsRNA not targeting
dystroglycan (see Materials and methods). In summary, our
results indicate that inhibiting the interaction between α- and β-
dystroglycan by Fab fragments or dystroglycan synthesis by
RNAi induced an increase in the radial thickness of the
neuroepithelial cell layer in the early developing CNS.
Altered morphology of neuroepithelial cells in thickenings
To investigate the morphology of neuroepithelial cells in
more detail we stained sections of neuroepithelium with
antibodies against vimentin, an intermediate filament protein
expressed in neuroepithelial cells (Lemmon and Rieser, 1983).
While in control tissues the anti-vimentin staining outlined the
palisade-like radial structure of neuroepithelial cells with their
processes in the pseudostratified neuroepithelium (Fig. 1G), this
radial staining pattern was lost after Fab fragment injection (Fig.
1H) and the pattern of the anti-vimentin immunoreactivity
appeared round or oval-shaped (compare Figs. 1G and H). A
similarly altered staining pattern was observed in tecta that
received Fab-fragment injections as well as in retinae treated
with dystroglycan RNAi (see Figure S3 in supplementary
material). Since the vimentin immunoreactivity reflects the
overall shape of neuroepithelial cells, our results suggest that
Fig. 1. Increase in radial thickness of the retinal and tectal neuroepithelium after anti-dystroglycan Fab fragment injection or RNAi electroporation. Cryostat sections of
E9 retinal (A, B, E, F, G, H) or E7 tectal tissue (C, D) after injection of preimmune serum (A, C, G) or of affinity-purified anti-dystroglycan Fab fragments (B, D, H)
into the vitreous (A, B, E, F) or into the mesencephalic brain ventricle (C, D) resulted in the formation of thickenings of the neuroepithelial cell wall. The thickenings
developed by growth of the retina into the vitreous (V in panels A, B) or by growth of the tectum into the ventricle (V in panels C, D). The border between the retina and
the pigment epithelium, marked by a dashed line in panels A and B, remained smooth. In ovo electroporation of anti-α-dystroglycan (E) or anti-β-dystroglycan (F)
siRNA resulted in the formation of a similar increase in radial thickness of the neuroepithelium. To illustrate the spatially restricted influence of the RNAi, parts of the
retina which were not affected are shown on the right side of panels E and F. Note the difference in the immunoreactivity of α-dystroglycan (panel E) and β-
dystroglycan (panel F) co-distributing with the increased retinal thickness. Analysis of the vimentin staining at high magnification showed the altered morphology of
neuroepithelial cells. While vimentin in neuroepithelial cells from control retinae had a radial distribution, spanning the width between pigment epithelium and vitreous
(G), they had lost this palisade-like morphology after injection of the Fab fragments and the vimentin immunoreactivity appeared round or oval-shaped (H). Scale bar
in panels A, B: 150 μm; C, D: 100 μm; E, F: 20 μm; G, H: 20 μm.
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neuroepithelial cells lose their radially oriented processes and
adopt a more round or oval morphology.
The loss of the radial morphology of neuroepithelial cells
after inhibition of dystroglycan interaction or synthesis together
with the known concentration of dystroglycan in their endfeetsuggested that the DGC might be involved in anchoring
neuroepithelial cell endfeet to the basal lamina. To investigate
this possibility, we transfected neuroepithelial cells by in ovo
microelectroporation with constructs coding for mutated
dystroglycan proteins. One construct had the C-terminal most
15 amino acids deleted, rendering the encoded dystroglycan
Fig. 2. In ovo electroporation of mutated dystroglycan constructs. Retinal neuroepithelial cells were transfected at E2 (HH stage 11) by in ovo microelectroporation
with the empty pMES vector (A–C), or with the pMES vector containing wt-dystroglycan (wt-dyg; D–F), non-cleavable dystroglycan (nc-dyg; G–I) or truncated
dystroglycan (J–L), respectively. The EGFP fluorescence of the transfected cells 4 days after transfection is shown in panels A, D, G, J and the vimentin staining of the
same area is shown in panels B, E, H, K. A representative individual transfected neuroepithelial cell is shown in panels C, F, I, L. Note that the retina diameter is not
affected by transfection of empty vector or wt-dystroglycan and that the neuroepithelial cells retain their radial morphology. Transfection of the non-cleavable
dystroglycan construct resulted in a considerably thinner retina (compare panels G, H with A, B), although the overall radial morphology of the transfected
neuroepithelial cells remained unaltered (panel I). In contrast, transfection of the truncated dystroglycan construct resulted in the loss of the radial structure of the
transfected neuroepithelial cells, indicated by the round labeling after vimentin staining (panel K) as well as after analysis of the EGFP fluorescence of individual
transfected cells at high magnification (panel L). Note that only a part of the affected retina is shown in panels J and K and that a lower magnification was used in these
two panels. All panels are oriented with vitreal (basal) side of the neuroepithelium is facing down. The pigment epithelium (PE) is outlined by a dashed line in panels G
and H. Scale bars in panels H and K: 50 μm; scale bar for C, F, I shown in L: 10 μm.
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and utrophin. The other construct had a mutated proteolytic
cleavage site so that the precursor protein could not be cleaved
into the α- and β-dystroglycan subunit (Esapa et al., 2003).
Both constructs were cloned into the pMES vector (Swartz et
al., 2001) which contains an internal ribosomal entry site
regulating the simultaneous expression of EGFP, allowing the
discrimination of transfected from untransfected cells. While inovo electroporation of empty pMES vector or pMES containing
wild type dystroglycan did not influence the overall eye
structure, electroporation of the non-cleavable construct
significantly reduced the size of the eyes (2.1±0.9 mm
compared to 3.4±0.5 mm in pMES or wt-dystroglycan treated
retinae; mean eye diameter±S.E.M. with N=3; determined at
E6, 4 days after electroporation). To investigate these changes in
more detail, we analyzed the overall retinal structure and the
Fig. 3. Quantification of retina width after in ovo electroporation. The width of
retinal areas transfected with either the empty vector (pMES), with vector
containing wt-dystroglycan, non-cleavable dystroglycan or truncated dystrogly-
can, respectively, was determined (black bars) and compared to the width of the
corresponding contralateral non-treated eyes of the same embryo (grey bars).
The width of the retina of all contralateral eyes was similar to the width of eyes
transfected with either empty vector or with vector containing the wt-
dystroglycan, demonstrating that the transfection by in ovo electroporation
itself had no effect on retinal structure. In contrast, the width of the retina was
significantly reduced in regions transfected with non-cleavable dystroglycan and
significantly increased in regions transfected with truncated dystroglycan. The
values represent the mean±S.E.M. from three independent experiments. Ten
transfected areas were analyzed in each experiment. P values in two-tailed
t-tests are indicated.
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with the different constructs. Fig. 2 shows parts of transfected
retinae (indicated by the EGFP fluorescence; panels A, D, G, J)
and the corresponding regions stained with anti-vimentin
antibodies (B, E, H, K) to reveal the morphology of
neuroepithelial cells. Expression of the empty pMES vector or
of pMES containing wt-dystroglycan did not influence the
overall retinal structure or the radial morphology of neuroe-
pithelial cells (Figs. 2A, B, D, E). Transfection of the non-
cleavable construct, however, resulted in a significant reduction
of the width of the retinal neuroepithelium (Figs. 2G, H). In
contrast, in ovo electroporation of the truncated dystroglycanFig. 4. Mutated dystroglycan expression influences neuroepithelial cell proliferation
HH stage 11 with either the empty pMES vector (A, E, I), vector containing wt-dy
truncated-dystroglycan (tr-dyg; D, H, L), respectively, and analyzed 4 days later at E 6
areas were subsequently analyzed using the EGFP fluorescence (A–D), bisbenzimide
primarily localized at the vitreal side of the retina (labeled by a dashed line in pane
wt-dystroglycan, or with the non-cleavable dystroglycan (panels I, J, and K, resp
transfection with the non-cleavable construct (compare panel K with I and J). Moreov
transfection with the truncated dystroglycan construct (compare panel L with I and J).
total number of cells in 100 μm segments of retinae (panel M), either transfected with
(grey bar). The values represent the mean±S.E.M. with N=3 in all experiments. P
experiment. Panel N shows a high magnification of panel G to illustrate the concentra
their absence from the apical side of the retina after transfection with the non-cleavabl
in panels C, G, and N. Panels O and P show bisbenzimide-labeled nuclei after transfe
their oval and round morphology, respectively. The vitreal (basal) side of the retina is a
H, and L compared to panels A–K, respectively. Scale bar A–N: 100 μm; O, P: 20construct increased retinal thickness and induced the formation
of thickenings similar to those formed after Fab fragment
injection and anti-dystroglycan RNAi treatment (Figs. 2J, K).
Staining of areas transfected with the truncated dystroglycan
construct using antibodies against vimentin also showed that the
retinal neuroepithelium had lost its palisade-like pseudostrati-
fied structure and that neuroepithelial cells had lost their radial
orientation and had developed a morphology similar to
neuroepithelial cells treated with Fab fragments or anti-dystro-
glycan RNAi (compare Figs. 2B, E, H with K).
To investigate the morphology of transfected neuroepithelial
cells in more detail, we analyzed the EGFP fluorescence of
transfected neuroepithelial cells at high magnification. In order
to analyze the morphology of individual cells we restricted our
analysis to areas with a very low transfection rate. The right
panels in Fig. 2 show representative individual cells transfected
with empty pMES vector (panel C), wt-dystroglycan (panel F),
non-cleavable dystroglycan (panel I), and truncated dystrogly-
can (panel L). Note that the EGFP fluorescence fills the entire
neuroepithelial cells, including the processes. Neuroepithelial
cells transfected with pMES, wt-dystroglycan or non-cleavable
dystroglycan maintained their palisade-like radial structure and
spanned the entire width between the inner limiting membrane
and the ventricular (pigment epithelium) side. However, the
length along the apical-basal axis of the neuroepithelial cells
transfected with the non-cleavable construct was significantly
reduced (Fig. 2I), most likely explaining the decreased eye size
observed after transfection of non-cleavable dystroglycan. In
contrast, all neuroepithelial cells transfected with the truncated
dystroglycan construct appeared round in EGFP fluorescence
analysis as indicated in Fig. 2L which shows one representative
cell out of a group of several labeled cells within a single
section. These data support the hypothesis that inhibition of the
interaction between α- and β-dystroglycan, inhibition of
dystroglycan synthesis, or expression of truncated dystroglycan
results in the loss of the radial structure of neuroepithelial cells.
To quantify these changes, the thickness of transfected
retinal areas (indicated by the EGFP fluorescence) was
determined (black bars in Fig. 3) and directly compared to the
retinal thickness of the contralateral non-transfected eye (grey
bars in Fig. 3). While in ovo electroporation of wt-dystroglycan
or of the empty pMES vector had no effect on the width of the. To analyze the proliferation of neuroepithelial cells, retinae were transfected at
stroglycan (wt-dyg; B, F, J), non-cleavable dystroglycan (nc-dyg; C, G, K) or
. Proliferating cells were marked by a 3-h pulse of BrdU. The cells in transfected
staining (E–H) and antibodies against BrdU (I–L). Nuclei labeled by BrdU were
ls C, G, K and N) in neuroepithelial cells transfected with empty vector, with
ectively). However, considerably less BrdU-labeled cells were observed after
er, a significant increase in the number of BrdU-labeled cells was observed after
The results were quantified by determining the percent of BrdU-labeled cells per
the indicated cDNA (black bar) or of non-transfected contralateral control retinae
values for two-tailed t-tests are indicated. Ten segments were analyzed in each
tion of nuclei at the vitreal side (marked by a dashed line in panels G and N) and
e dystroglycan construct. Note that parts of the pigment epithelium (PE) is shown
ction with wt-dystroglycan (O) and with truncated dystroglycan (P) to illustrate
t the bottom of each panel. Note that a lower magnification was used in panels D,
μm.
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70 J.E. Schröder et al. / Developmental Biology 307 (2007) 62–78neuroepithelium, transfection with the non-cleavable construct
reduced the thickness to approximately one-third of control
values, while transfection with the truncated dystroglycan
cDNA had the opposite effect and increased the thickness of the
retina by approximately 50%.
Increase of retinal radial thickness result from
hyperproliferation of neuroepithelial cells
To analyze if the increased width of the retina was the result
of an increased proliferation of neuroepithelial cells, we labeled
dividing cells 4 days after electroporation by a 3-h pulse of
BrdU and subsequent staining with anti-BrdU antibodies. As
shown in Fig. 4, BrdU-labeled nuclei were localized primarily at
the vitreal side of retinae transfected with pMES or with wt-
dystroglycan (Figs. 4I, J). We observed an increased number of
BrdU-labeled cells after electroporation of the truncated
dystroglycan construct and these cells were localized through-
out the retinal width (Fig. 4L). Likewise, intraocular injection of
anti-dystroglycan Fab fragments lead to an increase in number
and to a more widespread distribution of the BrdU-labeled cells.
In contrast, electroporation of the non-cleavable dystroglycan
construct reduced the number of BrdU-labeled neuroepithelial
cells (Fig. 4K). These results were quantified by comparing the
percentage of BrdU-labeled cells with the total number of cells
(as determined by bisbenzimide nuclear staining; Figs. 4E–H)
within 100 μm retina segments (black bars in Fig. 4M). The
contralateral untreated eyes served as controls (grey bars in Fig.
4M). The quantification demonstrated that 4 days after
transfection the number of BrdU-labeled cells was almost
doubled in areas transfected with truncated dystroglycan and
reduced to almost half after electroporation of the non-cleavable
dystroglycan. Similar results were obtained after intravitreal
injection of anti-dystroglycan Fab fragments (93±13.5 BrdU-
labeled cells, compared to 53±11.1 cells in preimmune serum-
injected retinae; mean±S.E.M. with N=3; analysis at E9 4 days
after first Fab fragment injection) and after injection of the Fab
fragments into the ventricle of the mesencephalon (99±4.6 cells
labeled by anti-BrdU antibodies in 100 μm segments after
injection of the preimmune serum compared to 45±5 cells in
control retinae; mean±S.E.M. with N=3; analysis at E7, 3 days
after first Fab fragment injection). These results demonstrate
that the increased thickness of the neuroepithelium after
transfection with the truncated dystroglycan construct or after
Fab fragment injection is due to an increased proliferation of
neuroepithelial cells. Moreover, the decrease in neuroepithelialFig. 5. Neurogenesis is altered after transfection of dystroglycan constructs. The EGF
AChE staining for postmitotic neurons (panels I–L) in cryostat sections of E6 retinae
dyg; B, F, J), non-cleavable dystroglycan (nc-dyg; C, G, K) or truncated dystroglycan
side facing down. While under control conditions retinal AChE-positive postmitotic n
vitreal border of the retina, AChE-labeled cells were more numerous and had a mor
construct (compare panels I, J with panel L). In contrast, very few if any AChE
dystroglycan construct (panel K). Quantification of these results is shown in panel M
section was determined in retinae transfected with the indicated constructs (black ba
bars). The values represent the mean±S.E.M. with N=3 in all cases. P values for tw
used in panels D, H, L. Scale bars in panels I and L: 100 μm.cell proliferation after electroporation of the non-cleavable
dystroglycan construct suggests an essential role for the post-
translational processing of dystroglycan in the regulation of the
cell cycle of neuroepithelial cells. The reduced proliferation rate
is most likely also the explanation for the reduced size of eyes
transfected with the non-cleavable dystroglycan construct.
Interestingly we noted that the nuclei of neuroepithelial cells
transfected with non-cleavable dystroglycan were not evenly
distributed throughout the width of the retina, but instead had
accumulated at the vitreal (basal) side (Fig. 4N). Together with
the observed reduced proliferation rate, this result suggests that
the interkinetic migration of the nucleus of cells expressing the
non-cleavable dystroglycan was inhibited at a particular
position and that the cell cycle of neuroepithelial cells was
not able to progress beyond a particular phase. Furthermore,
electroporation with the truncated dystroglycan construct also
influenced nuclear morphology. While control cells transfected
with pMES, wt-dystroglycan, or non-cleavable dystroglycan
had an oval shaped nucleus, nuclei of cells transfected with the
truncated dystroglycan construct were round (compare bisben-
zimide staining in Figs. 4O and P). Thus, the treatments that
resulted in the loss of the radial structure of the neuroepithelial
cells also changed the morphology of the nuclei.
Previous studies had shown that impaired dystroglycan
function results in the formation of ectopias, heterotopias and
other CNS abnormalities due to a fragmented basal lamina (glia
limitans; Moore et al., 2002; Saito et al., 1999; Kurahashi et al.,
2005; Lee et al., 2005). To rule out the possibility that the
increased thickness of the retinal and tectal neuroepithelium
developed due to a ruptured basal lamina, we determined the
integrity of the inner limiting membrane of the retina after in
ovo electroporation of wt- and mutated dystroglycan cDNA by
staining with antibodies against agrin and laminin. We found no
evidence for basal lamina fragmentation in retinae transfected
with any of the dystroglycan constructs (Figure S4 in
supplementary material). Likewise, we did not observe basal
lamina fragmentation in eyes or tecta treated with the anti-
dystroglycan Fab fragments (data not shown). These results
demonstrate that the increase in retinal and tectal thickness and
the increased number of neuroepithelial cells were not the result
of a fragmented basal lamina.
Dystroglycan influences neurogenesis
To determine if the increased proliferation observed after
inhibition of dystroglycan interaction or synthesis as well asP fluorescence (panels A–D), bisbenzimide nuclear staining (panels E–H), and
transfected at E2 with either empty vector (pMES; A, E, I), wt-dystroglycan (wt-
cDNA (tr-dyg; D, H, L) are shown. All panels are oriented with the vitreal (basal)
eurons (representing retinal ganglion cells) were localized in a single layer at the
e widespread distribution in retinae transfected with the truncated dystroglycan
-labeled cells could be detected in retinae transfected with the non-cleavable
. The percentage of AChE-labeled cells per total number of cells in a 100 μm
rs) and compared to the corresponding non-transfected contralateral retina (grey
o-tailed t-tests are indicated in panel M. Note that a smaller magnification was
71J.E. Schröder et al. / Developmental Biology 307 (2007) 62–78after transfection of truncated dystroglycan was accompanied
by an increase in neuronal differentiation, we stained treated
retinae with antibodies against acetylcholine esterase (AChE).
AChE has previously been shown to be a marker for postmitoticneurons in the developing chick CNS (Layer and Sporns, 1987).
In retinae transfected with either pMES alone (Figs. 5A, E, I) or
with pMES containing wt-dystroglycan (Figs. 5B, F, J) post-
mitotic neurons were found in a single layer (ganglion cell
72 J.E. Schröder et al. / Developmental Biology 307 (2007) 62–78layer; GCL) at the border between retina and vitreous. On the
other hand, transfection of non-cleavable dystroglycan resulted
in the differentiation of significantly less postmitotic neurons,
with large areas of the retina apparently without AChE
immunoreactivity (Figs. 5C, G, K). In contrast, retinae trans-
fected with the truncated dystroglycan construct had many more
AChE-positive cells compared to control retinae, suggesting an
increased neuronal differentiation of neuroepithelial cells.
However, the AChE-positive cells were not concentrated at
the vitreal border of the retina but instead found throughout the
retinal neuropil (Figs. 5D, H, L). These results were quantified
by determining the percent of AChE-positive cells per total
number of cells (determined by bisbenzimide staining) in
100 μm wide retinal segments (black bars in Fig. 5M) and
comparing this number to the percent of labeled cells in the
contralateral, non-treated retina of the same embryo (grey bars
in Fig. 5M). While transfection of empty pMES vector or of wt-
dystroglycan had no effect on the number of AChE-positive
cells, the number of labeled cells was reduced by approximately
one-third after transfection with the non-cleavable dystroglycan
construct and increased by approximately one-third after
transfection with the truncated dystroglycan construct (Fig.
5M). Similar differences were observed when anti-Thy-1
antibodies or anti-neurofilament NF68 antibodies were used
to label postmitotic neurons or their neurites (data not shown).
Moreover, we found a similar increase in the number of
postmitotic neurons after Fab fragment injection into the
vitreous of the eye (data not shown) or into the ventricle of
the mesencephalon (Figure S5 in supplementary material). In
summary, our results demonstrate that inhibition of dystrogly-
can interaction by Fab fragments, or of dystroglycan synthesis
by RNAi, or overexpression of the truncated dystroglycan
construct resulted in the differentiation of more postmitotic
neurons in the retina and in the tectum. These neurons were
however ectopically localized and did not accumulate in the
appropriate layer. In contrast, expression of the non-cleavable
dystroglycan protein severely reduced the number of post-
mitotic neurons.Fig. 6. Distribution of basally concentrated proteins in neuroepithelial cells after trans
with wt-dystroglycan (panels A–C), non-cleavable (D–F) and truncated dystrogly
dystrobrevin-1 (α-DB-1; panels B, E, H) and β1-integrin (panels C, F, I). Similar ex
three antibodies in retinae transfected with non-cleavable dystroglycan (panels E, F) a
truncated dystroglycan construct (panels G, H, I). Scale bar in panel A: 20 μm.Distribution of basally concentrated proteins
To determine if interfering with dystroglycan function had an
influence on proteins concentrated in the endfeet, we stained
neuroepithelial cells transfected with the different dystroglycan
constructs using a number of antibodies against basally
concentrated proteins, including other components of the
DGC. Utrophin has been shown to interact with dystroglycan
in skeletal muscle and to be concentrated in the endfeet of
neuroepithelial cells (Blank et al., 2002). Staining of retinal
neuroepithelial cells transfected with pMES or with pMES
containing wt-dystroglycan confirmed the concentration of
utrophin at the vitreal border of the retina (Fig. 6A). In contrast,
utrophin immunoreactivity was reduced at the retina–vitreous
interface in eyes transfected with the non-cleavable construct
(Fig. 6D). Likewise, staining intensities with antibodies against
α-dystrobrevin-1 or against β1-integrin in neuroepithelial cell
endfeet were significantly reduced in regions transfected with
non-cleavable dystroglycan (Figs. 6E, F), compared to cells
transfected with wt-dystroglycan. In contrast, we found a
redistribution of utrophin, α-dystrobrevin-1 and β1-integrin in
cells transfected with the truncated dystroglycan (Figs. 6G, H, I).
All proteins were detectable in a much broader area, and the
immunoreactivities were not strictly concentrated at the border
between retina and vitreous. Likewise, staining of cells
transfected with the truncated dystroglycan construct using an
antibody against the last 15 amino acids of β-dystroglycan
(which only labels endogenous dystroglycan, since this epitope
is missing in the transfected truncated dystroglycan protein),
showed a loss of the polarized distribution of endogenous β-
dystroglycan in the transfected cells (data not shown). All
changes were restricted to the transfected areas (identified by
EGFP fluorescence) and not observed in untransfected areas of
the same tissue. In summary, the results show that the
subcellular concentration of the DGC and of other proteins in
the endfeet of neuroepithelial cells was severely compromised
in neuroepithelial cells transfected with the truncated- or with
the non-cleavable dystroglycan construct.fection of the dystroglycan constructs. Cryostat sections of E6 retinae transfected
can (G–I) were stained with antibodies against utrophin (panels A, D, G), α-
posure times were used in all cases. Note the reduced immunoreactivity with all
nd the widespread distribution of the three proteins in retinae transfected with the
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axonal growth
Our results so far suggested that interfering with dystrogly-
can function or synthesis caused a loss of the radial morphology
of neuroepithelial cells and the loss of specializations at the
contact site of their endfeet to the basal lamina. Since the
endfeet, in addition to anchoring neuroepithelial cells to the
basal lamina, also provide guidance cues for growing axons, we
reasoned that the loss of the radial morphology and the loss of
the endfeet basal lamina attachment might influence axonal
orientation. We therefore investigated the orientation of axonal
growth in retinae transfected with the various constructs. Fig. 7
shows areas of flat-mounted retinae 3 days after electroporation
at low (panels A–D) and at high magnification (panels E–H)
stained with an antibody against Ng-CAM, a cell adhesion
molecule which is expressed on all long-distance projecting
neurons and which in the retina and tectum labels the axons of
postmitotic neurons without staining of their cell bodies (Halfter
et al., 1987; Kröger and Schwarz, 1990). In non-transfected
retinae or retinae transfected with pMES, axons of retinal
ganglion cells grew centripetally in almost-parallel fascicles
towards the exit of the optic nerve head (Figs. 7A, E). This
overall pattern was maintained in retinae transfected with wt-
dystroglycan or with non-cleavable dystroglycan (Figs. 7B, F,
C, G). In contrast, expression of truncated dystroglycan drama-
tically altered the orientation of retinal ganglion cell axons
(Figs. 7D, H). In the transfected areas (indicated by an asterisk
in Fig. 7D) we observed a complete loss of the centripetalFig. 7. Altered axonal growth after transfection of truncated dystroglycan. Flat-mou
shown at low (panels A–D) and at high (panels E–H) magnification. Transfection o
cleavable dystroglycan (C, G) did not influence the directionality of retinal ganglion
switching between the fascicles in areas transfected with the non-cleavable construct (
the optic fissure and the exit of the optic nerve (located on the left side in panels A–D
truncated dystroglycan construct (panels D and H). The fascicles were oriented in all d
that the loss of oriented axonal growth was only local and restricted to the area affegrowth, and a random orientation of the axons. A similar loss of
orientation was observed in retinae treated with anti-dystrogly-
can RNAi (data not shown). Moreover, tectobulbar axons in the
mesencephalon (Kröger and Schwarz, 1990) lost their ventrally
oriented growth after injection of the affinity-purified anti-
dystroglycan Fab fragments into the mesencephalic ventricle
(Figure S6 in supplementary material), demonstrating that the
loss of the orientation after interfering with dystroglycan
function could also be observed in other parts of the developing
CNS. Moreover, since dystroglycan is not expressed by
growing retinal or tectal axons, these data suggest a non cell
autonomous mechanism via altered neuroepithelial cells.
Discussion
Dystroglycan and other proteins of the DGC are highly
concentrated in the endfeet of neuroepithelial cells throughout
the CNS (Blank et al., 2002; Zaccaria et al., 2001; Luniardi et al.,
2006). Since one function of the DGC in skeletal muscle is the
formation of a molecular bridge between the cytoskeleton and
the basal lamina and to provide a scaffold for the attachment of
proteins, we hypothesized that it might play similar roles in
neuroepithelial cells of the developing CNS. Here we show that
interfering with dystroglycan function in neuroepithelial cells in
vivo by injection of anti-dystroglycan Fab fragments, inhibition
of dystroglycan synthesis or expression of a truncated
dystroglycan cDNA results in the loss of their radial morphol-
ogy, in hyperproliferation with subsequent thickening of the
neuroepithelium, and in an increased number of postmitoticnted E6 retinal wholemounts were labeled with antibodies against NgCAM and
f retinae with the empty vector (pMES; A, E), wt-dystroglycan (B, F) or non-
cell axon growth. Although we observed a slightly increased number of axons
compare panels E and G), the overall orientation of growth was directed towards
). In contrast, this centripetal orientation was lost in retinae transfected with the
irections and many axons failed to reach the optic nerve and to exit the eye. Note
cted by the transfection. Scale bar in panels A: 200 μm; E: 100 μm.
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glycan in neuroepithelial cells had the opposite effect, i.e. a
reduced thickness of the neuroepithelium, less proliferation, and
a reduced number of differentiated postmitotic neurons. In
summary, these data demonstrate a key role for dystroglycan in
neuroepithelial cell structure, proliferation and differentiation.
Neuroepithelial cells are multipotent precursor cells for
neurons and glial cells of the CNS (for review see Kriegstein and
Götz, 2003; Götz and Huttner, 2005). Neuroepithelial cells have
a radial morphology and span the entire width of the
neuroepithelium extending from the lumen of the ventricle to
the pial surface via processes. They are polar cells with an apical
(ventricular) and a basal (pial) side (for review see Götz and
Huttner, 2005). Both sides are molecularly, morphologically and
functionally specialized. For example, at their basal side
neuroepithelial cells have a process with an endfoot at its tip,
which anchors the cell to a basal lamina (glia limitans in the brain
or inner limitingmembrane in the retina) and, thus, maintains the
radial morphology. The radial structure of neuroepithelial cells is
important for at least two processes: The neuroepithelial cell
nucleus undergoes an interkinetic migration, translocating
within the cell between the ventricular and the pial surface.
Different stages of the cell cycle are correlated with specific
positions of the nucleus during this translocation (Sauer, 1935;
Götz and Huttner, 2005). The radial morphology of neuroe-
pithelial cells and a polarized cytoskeleton are necessary for the
translocation of the nucleus. In addition, the radial structure of
the neuroepithelial cells is required for the migration of
differentiated neuroblasts to their appropriate layer (for review
see Kriegstein and Noctor, 2004).
In this study we provide several lines of evidence for a
fundamental role of dystroglycan in maintaining the radial
morphology of neuroepithelial cells in vivo: First, interfering
with the interaction between α- and β-dystroglycan by injection
of affinity-purified anti-dystroglycan Fab fragments, or inhibi-
tion of dystroglycan synthesis using RNAi or overexpression by
in ovo electroporation of a dystroglycan construct which lacks
the C-terminal most 15 amino acid and, thus, is incapable of
interacting with dystrophin or utrophin, lead to a loss of the
radial morphology of neuroepithelial cells and to the develop-
ment of a round or oval shape. Second, the same treatments also
changed the shape of the nuclei from elongated to round,
suggesting that the apically–basally oriented cytoskeleton was
not able to form or to maintain the radial structure of
neuroepithelial cells and their nuclei. Third, the polarized
distribution of several proteins, including utrophin, β1-integrin
and α-dystrobrevin-1, was altered from being highly concen-
trated in the endfeet to a broader distribution. Fourth, these
different treatments also affected the orientation of axons that
use endfeet-derived signals to navigate towards their target
tissue, consistent with the idea that the processes and their
endfeet were not present under these conditions. Finally,
postmitotic neurons were found widely dispersed within the
retina and tectum, suggesting that migration of postmitotic
neurons into the appropriate layer was compromised. In
summary, our data support the hypothesis that in endfeet of
neuroepithelial cells dystroglycan and the DGC form amolecular connection between the cytoskeleton and the basal
lamina and that interfering with dystroglycan function or
synthesis detaches the endfoot from the basal lamina resulting
in an altered cytoskeleton, in a loss of the radial structure, and in
a loss of the polarized distribution of basally concentrated
proteins.
Why does transfection of the truncated dystroglycan result in
the same structural changes of neuroepithelial cells as inhibition
of dystroglycan interaction by Fab fragments or inhibition of
dystroglycan synthesis? One possibility is that the lack of the
intracellular interaction site interrupts the connection between
extracellular matrix and cytoskeleton, resulting in the loss of
adhesion between the neuroepithelial cell endfoot and the basal
lamina. However, an alternative and possibly more likely
explanation might be that the lack of the intracellular interaction
domain of β-dystroglycan with dystrophin and utrophin does
not allow the post-translational assembly of the DGC and
interferes with the polarized transport of the complex to the
endfeet. Previous studies in skeletal muscle and CNS tissue
have demonstrated that mutations in individual components of
the DGC influence the assembly of the complex, leading to an
absence or redistribution of most if not all other DGC proteins
from the plasma membrane (see for example Cohn et al., 2002;
Lee et al., 2005). We suggest that a similar mechanism applies
to neuroepithelial cells. In agreement with this possibility we
show that several DGC components, normally concentrated in
the neuroepithelial cell endfeet, including endogenous β-
dystroglycan, utrophin, and α-dystrobrevin-1, have an altered
distribution in cells transfected with truncated dystroglycan.
Thus, our results suggest that in neuroepithelial cells truncated
dystroglycan acts in a dominant-negative manner by interfering
with the assembly and subcellular concentration of the DGC in
neuroepithelial cell endfeet.
Previous studies have demonstrated that integrins are
important for the adhesion of neuroepithelial cell endfeet to
the basal lamina. For example, CNS-specific deletion of the β1-
integrins in transgenic mice resulted in a loss of glial cell endfeet
anchorage, altered meningeal basement membrane formation
and, as a consequence, altered cortical lamination (Graus-Porta
et al., 2001; Haubst et al., 2006). In this study we provide
evidence that dystroglycan is also involved in the adhesion of
neuroepithelial cell endfeet to the basal lamina raising the
possibility that in the developing CNS both proteins might have
overlapping functions or might influence each other. Several
studies have suggested a functional influence of integrins on the
dystrophin associated protein complex (see for example Burkin
et al., 2001; Cerna et al., 2006). In agreement with this we show
that the distribution of β1-integrins in retinae treated with RNAi
or with affinity-purified Fab fragments, or transfected with the
truncated dystroglycan construct was altered, suggesting that
dystroglycan is able to influence β1-integrin distribution in
endfeet of neuroepithelial cells. It remains to be determined,
however, if this is a direct consequence of the dystroglycan loss
of function, or an indirect, caused for example by the loss of the
endfeet and the subsequent lack of basal specializations.
In addition to the altered morphology, interfering with
dystroglycan function or synthesis also induced hyperprolifera-
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thickenings in the retina and tectum. Conversely, rendering the
interaction between α- and β-dystroglycan permanent by
expression of non-cleavable dystroglycan reduced the width of
the neuroepithelium and the number of proliferating cells,
demonstrating that dystroglycan influences the proliferation of
neuroepithelial cells in the developing brain. Concomitant with
the hyperproliferation we observed a change in the morphology
of the nuclei from oval/elongated to a round shape. Since an
elongated shape is typical for nuclei during interkinetic nuclear
migration, whereas a round morphology is adopted when
migration has stopped (Haubensak et al., 2004), this result
supports the idea that interfering with dystroglycan function or
synthesis influences neuroepithelial cell proliferation. In agree-
ment with this hypothesis, mice with a GFAP promoter-
mediated brain-specific deletion of dystroglycan showed an
increase in brain weight of approximately 20% without
simultaneous increase in body weight (Moore et al., 2002). It
remains to be determined however, how dystroglycan influences
neuroepithelial cell number. One possibility to explain the
altered proliferation would be an increase or decrease in
apoptosis. However, we did not observe fragmented nuclei or
pycnotic cells after transfection of the mutated dystroglycan
constructs or after Fab fragment injection, making this
possibility rather unlikely. It appears more likely that similar to
the role of the DGC in skeletal muscle inhibition of dystroglycan
function detaches the endfeet from the basal lamina and disrupts
the neuroepithelial cell polarity. Dystroglycan has been shown to
be important for the polarity of epithelial cell (Durbeej et al.,
1995, 2001; Muschler et al., 2002; Deng et al., 2003; Shcherbata
et al., 2007). In analogy, interference with dystroglycan function
in neuroepithelial cells might lead to a loss of their polarity with a
subsequently altered proliferation. However, since neither the
CNS-specific deletion of β1-integrin (Graus-Porta et al., 2001;
Haubst et al., 2006), nor the removal of the pia basal lamina by
either genetic means (Halfter et al., 2002) or by collagenase
injection (Halfter and Schurer, 1998) resulted in a phenotype
similar to the one described in our study, the simple mechanical
detachment of the neuroepithelial cell endfeet from the basal
lamina alone is not sufficient to explain the increased pro-
liferation of neuroepithelial cells. Instead, it appears more likely
that interfering with dystroglycan function influences intracel-
lular signaling processes involved in regulating the cell cycle. A
key regulator for neuroepithelial cell proliferation is the
intracellular phosphatase PTEN since loss of PTEN leads to
increased proliferation of neuroepithelial cells resulting in an
increase in brain size and altered CNS histoarchitecture (Groszer
et al., 2001). Interestingly, recent studies have provided evidence
that dystroglycan influences PTEN function (Muschler et al.,
2002; Sgambato et al., 2006). Although further studies are
needed, our results are consistent with the hypothesis that
dystroglycan is a component of the signaling cascade regulating
proliferation and differentiation of neuroepithelial stem cells.
Moreover, since several studies have demonstrated a role of
dystroglycan in the regulation of the cell cycle and cell division
(see for example Sgambato et al., 2003; Brennan et al., 2004),
the effect might not be restricted to neuroepithelial cells.The dystroglycan protein is synthesized as a single poly-
peptide which is posttranslationally cleaved into the α- and β-
subunit at a particular serine residue by an unknown protease
(Ibraghimov-Beskrovnaya et al., 1992; Deyst et al., 1995). The
significance of this cleavage is not known, but overexpression
of a non-cleavable dystroglycan protein in skeletal muscle lead
to muscular dystrophy in the transgenic mice, demonstrating
that dystroglycan cleavage is essential for normal muscle
function (Jayasinha et al., 2003). Heterologous expression of
non-cleavable chick dystroglycan revealed that proteolytic
cleavage was not necessary for synthesis, trafficking, normal
glycosylation, and membrane localization of the mutated
protein (Esapa et al., 2003). Likewise, overexpression of non-
cleavable dystroglycan in neuroepithelial cells by in ovo
electroporation did not apparently alter the expression of
endogenous dystroglycan and the protein encoded by the non-
cleavable construct had a molecular weight of approximately
160 kDa, consistent with normal glycosylation of the non-
cleaved dystroglycan protein. However, expression of this
construct in neuroepithelial cells resulted in less proliferation
and less neuronal differentiation. Thus, our results for the first
time provide evidence for a role of the proteolytic cleavage of
dystroglycan in the developing CNS. In addition, neuroepithe-
lial cells transfected with the non-cleavable dystroglycan
construct showed a concentration of nuclei at the basal side
raising the possibility that the interkinetic nuclear movement
was terminated around S-phase of the cell cycle. Interestingly,
recent studies have shown that heterologous expression of
dystroglycan protein and mRNA in epithelial cells is cell cycle
dependent and that suppression of dystroglycan synthesis with
siRNA resulted in inhibition of cell growth, accumulation of
cells in the S-phase of the cell cycle, and failure of dif-
ferentiation (Sgambato et al., 2006), suggesting a specific
influence of dystroglycan on proliferation that is not restricted
to neuroepithelial cells.
In a previous study, mice with a human GFAP promoter-
mediated brain-specific deletion of dystroglycan showed a
fragmented pial basal lamina (Moore et al., 2002). Likewise,
injection of morpholino antisense oligonucleotides into the four
cell stage Xenopus laevis caused disruption of the basal lamina
(Luniardi et al., 2006). In agreement with these results, we
observed areas with a disorganized basal lamina in retinae
transfected with RNAi targeting dystroglycan, suggesting that
the continuous expression of dystroglycan is important for basal
lamina assembly in the developing CNS. However, neither
injection of Fab fragments nor overexpression of mutated
dystroglycan constructs resulted in a fenestrated basal lamina, at
least within the 3–5 days of analysis in our study, indicating that
the hyperproliferation of neuroepithelial cells and the increased
number of postmitotic neurons are most likely not the result of
an impaired assembly of the extracellular matrix. Moreover,
while the morpholino-mediated loss of dystroglycan caused an
increased apoptosis, microphtalmia and formation of rosette-
like structures within the retina (Luniardi et al., 2006), we did
not observe signs of increased cell death and loss of
dystroglycan function was associated with an increased rate of
proliferation. However, in our study the antibodies or cDNAs
76 J.E. Schröder et al. / Developmental Biology 307 (2007) 62–78were applied directly to neuroepithelial cells and the short-term
effects within 3 to 4 days were investigated. In contrast,
Luniardi et al. (2006) applied the morpholino antisense already
at the four cell stage, and therefore analyzed long term effects of
dystroglycan loss of function already during gastrulation and
neurulation.
The interaction of α-dystroglycan with several extracellular
matrix proteins including laminin and agrin is mediated by the
carbohydrate side chains and mutations in at least three
glycosyltransferases cause an altered glycosylation and subse-
quently an impaired ability of dystroglycan to interact with
extracellular matrix proteins (for review see Martin-Rendon and
Blake, 2003; Muntoni et al., 2004). The mutations in the
glycosyltransferases cause three forms of congenital muscular
dystrophy: Walker–Warburg Syndrome, Muscle–Eye–Brain
Disease and Fukuyama Congenital Muscular Dystrophy. These
diseases are characterized by a progressive skeletal muscle
degeneration and a particularly severe brain and retina
phenotype, which includes hyperproliferation of neurons and
glial cells, heterotopias, disorganized layering, defects in
neuronal migration, fragmented basal laminae, and clusters of
neurons and glial cells ectopially in the subarachinoidal space
(for review see Muntoni et al., 2004). Likewise, mice with a
CNS-specific deletion of dystroglycan in GFAP-expressing
cells (Moore et al., 2002) or mice lacking one of the
glycosyltransferases (Takeda et al., 2003; Michele et al.,
2002; Kurahashi et al., 2005; Lee et al., 2005) develop a
similar phenotype in the CNS. Our studies suggest for the first
time that one of the main functions of dystroglycan and the
DGC during early stages of CNS development is the anchoring
of neuroepithelial cell endfeet to the basal lamina and suggest
that at least some of the CNS abnormalities observed in these
forms of congenital muscular dystrophy or in the corresponding
mouse models might be explained by an altered function of
dystroglycan or the DGC at the endfoot–basal lamina interface.
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